Brief: Regenxbio Highlights Key 2026 Catalysts And Announces Positive Long-Term Functional Outcomes In Lead Duchenne Gene Therapy Program
11/01/2026 20:01
Jan 11 (Reuters) - Regenxbio Inc RGNX.O: REGENXBIO HIGHLIGHTS KEY 2026 CATALYSTS AND ANNOUNCES POSITIVE LONG-TERM FUNCTIONAL OUTCOMES IN LEAD DUCHENNE GENE THERAPY PROGRAM REGENXBIO INC - NEW RGX-202 DATA SHOWS LONG-TERM EFFECT AT 18 MONTHS REGENXBIO INC - EXPECTING FDA PDUFA DECISION AND DATA READOUTS IN 2026 REGENXBIO INC - TO RECEIVE $100 MILLION PAYMENT FROM ABBVIE IN 1H 2026 REGENXBIO INC - EXPECTS PIVOTAL TRIAL DATA IN Q4 2026 Source text: ID:nPnbck1LKa Further company coverage: RGNX.O ((Reuters.Briefs@thomsonreuters.com;))